306 related articles for article (PubMed ID: 21047903)
1. Cancer epigenetics: from disruption of differentiation programs to the emergence of cancer stem cells.
Scaffidi P; Misteli T
Cold Spring Harb Symp Quant Biol; 2010; 75():251-8. PubMed ID: 21047903
[TBL] [Abstract][Full Text] [Related]
2. Xenopatients 2.0: reprogramming the epigenetic landscapes of patient-derived cancer genomes.
Menendez JA; Alarcón T; Corominas-Faja B; Cuyàs E; López-Bonet E; Martin AG; Vellon L
Cell Cycle; 2014; 13(3):358-70. PubMed ID: 24406535
[TBL] [Abstract][Full Text] [Related]
3. Current status in cancer cell reprogramming and its clinical implications.
Izgi K; Canatan H; Iskender B
J Cancer Res Clin Oncol; 2017 Mar; 143(3):371-383. PubMed ID: 27620745
[TBL] [Abstract][Full Text] [Related]
4. Induced pluripotent stem cell technology for dissecting the cancer epigenome.
Semi K; Yamada Y
Cancer Sci; 2015 Oct; 106(10):1251-6. PubMed ID: 26224327
[TBL] [Abstract][Full Text] [Related]
5. Epigenetics and Cancer Stem Cells: Unleashing, Hijacking, and Restricting Cellular Plasticity.
Wainwright EN; Scaffidi P
Trends Cancer; 2017 May; 3(5):372-386. PubMed ID: 28718414
[TBL] [Abstract][Full Text] [Related]
6. Parallels between artificial reprogramming and the biogenesis of cancer stem cells: Involvement of lncRNAs.
Rasmussen TP
Semin Cancer Biol; 2019 Aug; 57():36-44. PubMed ID: 30273656
[TBL] [Abstract][Full Text] [Related]
7. Cellular reprogramming and cancer development.
Semi K; Matsuda Y; Ohnishi K; Yamada Y
Int J Cancer; 2013 Mar; 132(6):1240-8. PubMed ID: 23180619
[TBL] [Abstract][Full Text] [Related]
8. "Reprogram Enablement" as an Assay for Identifying Early Oncogenic Pathways by Their Ability to Allow Neoplastic Cells to Reacquire an Epiblast State.
Kong Y; Gimple RC; McVicar RN; Hodges AP; Yin J; Liu Y; Zhan W; Snyder EY
Stem Cell Reports; 2020 Sep; 15(3):761-775. PubMed ID: 32795421
[TBL] [Abstract][Full Text] [Related]
9. Reprogramming cancer cells to pluripotency: an experimental tool for exploring cancer epigenetics.
Stricker S; Pollard S
Epigenetics; 2014 Jun; 9(6):798-802. PubMed ID: 24686321
[TBL] [Abstract][Full Text] [Related]
10. Obstacles in Renal Regenerative Medicine: Metabolic and Epigenetic Parallels Between Cellular Reprogramming and Kidney Cancer Oncogenesis.
Lichner Z; Mac-Way F; Yousef GM
Eur Urol Focus; 2019 Mar; 5(2):250-261. PubMed ID: 28847686
[TBL] [Abstract][Full Text] [Related]
11. The miR-302-Mediated Induction of Pluripotent Stem Cells (iPSC): Multiple Synergistic Reprogramming Mechanisms.
Ying SY; Fang W; Lin SL
Methods Mol Biol; 2018; 1733():283-304. PubMed ID: 29435941
[TBL] [Abstract][Full Text] [Related]
12. Metal carcinogen exposure induces cancer stem cell-like property through epigenetic reprograming: A novel mechanism of metal carcinogenesis.
Wang Z; Yang C
Semin Cancer Biol; 2019 Aug; 57():95-104. PubMed ID: 30641125
[TBL] [Abstract][Full Text] [Related]
13. Common themes of dedifferentiation in somatic cell reprogramming and cancer.
Daley GQ
Cold Spring Harb Symp Quant Biol; 2008; 73():171-4. PubMed ID: 19150965
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic regulation of somatic cell reprogramming.
Wang Y; Bi Y; Gao S
Curr Opin Genet Dev; 2017 Oct; 46():156-163. PubMed ID: 28823984
[TBL] [Abstract][Full Text] [Related]
15. Potential application of cell reprogramming techniques for cancer research.
Saito S; Lin YC; Nakamura Y; Eckner R; Wuputra K; Kuo KK; Lin CS; Yokoyama KK
Cell Mol Life Sci; 2019 Jan; 76(1):45-65. PubMed ID: 30283976
[TBL] [Abstract][Full Text] [Related]
16. The Dynamic Epigenetic Landscape of the Retina During Development, Reprogramming, and Tumorigenesis.
Aldiri I; Xu B; Wang L; Chen X; Hiler D; Griffiths L; Valentine M; Shirinifard A; Thiagarajan S; Sablauer A; Barabas ME; Zhang J; Johnson D; Frase S; Zhou X; Easton J; Zhang J; Mardis ER; Wilson RK; Downing JR; Dyer MA;
Neuron; 2017 May; 94(3):550-568.e10. PubMed ID: 28472656
[TBL] [Abstract][Full Text] [Related]
17. Metabolic and epigenetic reprogramming in the arsenic-induced cancer stem cells.
Li L; Bi Z; Wadgaonkar P; Lu Y; Zhang Q; Fu Y; Thakur C; Wang L; Chen F
Semin Cancer Biol; 2019 Aug; 57():10-18. PubMed ID: 31009762
[TBL] [Abstract][Full Text] [Related]
18. Concise review: dedifferentiation meets cancer development: proof of concept for epigenetic cancer.
Yamada Y; Haga H; Yamada Y
Stem Cells Transl Med; 2014 Oct; 3(10):1182-7. PubMed ID: 25122691
[TBL] [Abstract][Full Text] [Related]
19. Application of iPS cell technology to cancer epigenome study: uncovering the mechanism of cell status conversion for drug resistance in tumor.
Matsuda Y; Semi K; Yamada Y
Pathol Int; 2014 Jul; 64(7):299-308. PubMed ID: 25047500
[TBL] [Abstract][Full Text] [Related]
20. Epigenetics of cellular reprogramming.
Krishnakumar R; Blelloch RH
Curr Opin Genet Dev; 2013 Oct; 23(5):548-55. PubMed ID: 23948105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
